News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
The company is planning to expand its plant capacity in in Vapi
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The facility is a part of Lupin Manufacturing Solutions
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
